India's Manipal College prepares for nanotech drug-delivery revolution

The Times of India has a feature on India's Manipal College of Pharmaceutical Sciences (MCOPS) and its role in the use of nanotechnology in drug delivery. "Drug formulation companies are looking to make use of the drugs already in use, and finding better ways of delivering them using nanotechnology," professor Srinivasa Reddy told TOI.

The article goes on to state that MCOPS "has bagged major research projects" from the government in nanotech drug delivery research projects, most of them dealing with nanotech drug-delivery systems to treat life-threatening diseases such as cancer, Alzheimer's disease, heart disorders and diabetes.

Reddy said many pharmaceutical companies have used the research expertise of the MCOPS and have launched products. What MCOPS is focusing on now, he said, is nanotech drug-delivery products that can reduce costs and benefit developing countries like India.

"Over the long term, MCOPS have plans to focus nanotechnology applications into most therapeutic classes and encompass all types of formulations and delivery systems," Reddy said.

- read the story in The Times of India

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.